5-bromo-3-[1-(5-fluoro-2-methoxyphenyl)ethoxy]pyrazin-2-ylamine | 1346818-47-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-bromo-3-[1-(5-fluoro-2-methoxyphenyl)ethoxy]pyrazin-2-ylamine
• 英文别名: 5-Bromo-3-[1-(5-fluoro-2-methoxy-phenyl)-ethoxy]-pyrazin-2-ylamine；5-bromo-3-[1-(5-fluoro-2-methoxyphenyl)ethoxy]pyrazin-2-amine
• CAS: 1346818-47-0
• 化学式: C₁₃H₁₃BrFN₃O₂
• 分子量: 342.168
• InChiKey: PUUNZWFHRAVPRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-(5-氟-2-甲氧基苯基)乙醇 、 2-氨基-3,5-二溴吡嗪 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以42%的产率得到5-bromo-3-[1-(5-fluoro-2-methoxyphenyl)ethoxy]pyrazin-2-ylamine
  参考文献：
  名称：

  [EN] HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES DESTINÉS AU TRAITEMENT DE MALADIES

  摘要：

  公开号：

  WO2011138751A3

文献信息

• HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
  申请人：Bunnage Mark Edward

  公开号：US20130196952A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物，以及用于制备含有这些衍生物的组合物的中间体的制备过程和使用。根据本发明的化合物在许多与ALK蛋白有关或抑制ALK活性可能产生益处的疾病中非常有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• Alkoxy-substituted 2-aminopyridines as ALK inhibitors
  申请人：Bunnage Mark Edward

  公开号：US08916593B2

  公开（公告）日：2014-12-23

  The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物以及制备、制备中间体、含有和使用这些衍生物的组合物的过程。根据本发明的化合物在许多涉及ALK蛋白质或抑制ALK活性可能产生益处的疾病中有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP2566858A2

  公开（公告）日：2013-03-13
• US8916593B2
  申请人：——

  公开号：US8916593B2

  公开（公告）日：2014-12-23
• [EN] HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES DESTINÉS AU TRAITEMENT DE MALADIES
  申请人：PFIZER

  公开号：WO2011138751A2

  公开（公告）日：2011-11-10

  The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.